Logo image of GKOS

GLAUKOS CORP (GKOS) Stock Price, Quote, News and Overview

NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD

89.61  +1.31 (+1.48%)

GKOS Quote, Performance and Key Statistics

GLAUKOS CORP

NYSE:GKOS (4/22/2025, 3:30:01 PM)

89.61

+1.31 (+1.48%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High163.71
52 Week Low77.91
Market Cap5.12B
Shares57.09M
Float55.21M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)04-30 2025-04-30/amc
IPO06-25 2015-06-25


GKOS short term performance overview.The bars show the price performance of GKOS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

GKOS long term performance overview.The bars show the price performance of GKOS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60 80

The current stock price of GKOS is 89.61 USD. In the past month the price decreased by -13.65%. In the past year, price decreased by -11.24%.

GLAUKOS CORP / GKOS Daily stock chart

GKOS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 27.5 227.97B
ISRG INTUITIVE SURGICAL INC 64.96 170.59B
BSX BOSTON SCIENTIFIC CORP 37.74 140.11B
SYK STRYKER CORP 28.51 132.64B
MDT MEDTRONIC PLC 15.6 106.81B
BDX BECTON DICKINSON AND CO 14.3 57.13B
EW EDWARDS LIFESCIENCES CORP 26.85 41.36B
IDXX IDEXX LABORATORIES INC 37.33 34.03B
RMD RESMED INC 24.14 31.34B
GEHC GE HEALTHCARE TECHNOLOGY 13.67 28.11B
DXCM DEXCOM INC 40.11 25.95B
PHG KONINKLIJKE PHILIPS NVR- NY 15.37 22.68B

About GKOS

Company Profile

GKOS logo image Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The company develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Company Info

GLAUKOS CORP

1 Glaukos Way

Aliso Viejo CALIFORNIA 92672 US

CEO: Thomas W. Burns

Employees: 907

Company Website: https://www.glaukos.com

Investor Relations: https://investors.glaukos.com/

Phone: 19493679600

GLAUKOS CORP / GKOS FAQ

What is the stock price of GLAUKOS CORP today?

The current stock price of GKOS is 89.61 USD. The price increased by 1.48% in the last trading session.


What is the ticker symbol for GLAUKOS CORP stock?

The exchange symbol of GLAUKOS CORP is GKOS and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is GKOS stock listed?

GKOS stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for GLAUKOS CORP stock?

21 analysts have analysed GKOS and the average price target is 171.91 USD. This implies a price increase of 91.84% is expected in the next year compared to the current price of 89.61. Check the GLAUKOS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GLAUKOS CORP worth?

GLAUKOS CORP (GKOS) has a market capitalization of 5.12B USD. This makes GKOS a Mid Cap stock.


How many employees does GLAUKOS CORP have?

GLAUKOS CORP (GKOS) currently has 907 employees.


What are the support and resistance levels for GLAUKOS CORP (GKOS) stock?

GLAUKOS CORP (GKOS) has a support level at 85.49 and a resistance level at 89.44. Check the full technical report for a detailed analysis of GKOS support and resistance levels.


Is GLAUKOS CORP (GKOS) expected to grow?

The Revenue of GLAUKOS CORP (GKOS) is expected to grow by 26.9% in the next year. Check the estimates tab for more information on the GKOS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GLAUKOS CORP (GKOS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GLAUKOS CORP (GKOS) stock pay dividends?

GKOS does not pay a dividend.


When does GLAUKOS CORP (GKOS) report earnings?

GLAUKOS CORP (GKOS) will report earnings on 2025-04-30, after the market close.


What is the Price/Earnings (PE) ratio of GLAUKOS CORP (GKOS)?

GLAUKOS CORP (GKOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.9).


What is the Short Interest ratio of GLAUKOS CORP (GKOS) stock?

The outstanding short interest for GLAUKOS CORP (GKOS) is 6.47% of its float. Check the ownership tab for more information on the GKOS short interest.


GKOS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GKOS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to GKOS. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GKOS Financial Highlights

Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.9. The EPS increased by 16.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -15.02%
ROE -19.09%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%36.51%
Sales Q2Q%28.09%
EPS 1Y (TTM)16.3%
Revenue 1Y (TTM)21.85%

GKOS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to GKOS. The Buy consensus is the average rating of analysts ratings from 21 analysts.

For the next year, analysts expect an EPS growth of 47.44% and a revenue growth 26.9% for GKOS


Ownership
Inst Owners104.83%
Ins Owners3.22%
Short Float %6.47%
Short Ratio4.13
Analysts
Analysts83.81
Price Target171.91 (91.84%)
EPS Next Y47.44%
Revenue Next Year26.9%